Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.3%

2 terminated out of 38 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

8%

3 trials in Phase 3/4

Results Transparency

25%

6 of 24 completed with results

Key Signals

6 with results92% success

Data Visualizations

Phase Distribution

30Total
Not Applicable (19)
P 2 (8)
P 3 (2)
P 4 (1)

Trial Status

Completed24
Unknown7
Terminated2
Withdrawn1
Recruiting1
Active Not Recruiting1

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (38)

Showing 20 of 20 trials
NCT02820285Not ApplicableCompletedPrimary

Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH

NCT07497750Not ApplicableNot Yet RecruitingPrimary

Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial

NCT07378280Not ApplicableCompletedPrimary

Study to Investigate the Effect of L. Lactis CKDB001 Administration on Liver Aminotransferases in Subjects With NAFLD

NCT07086989Recruiting

Cardiovascular Risk in Children With Chronic Conditions Study

NCT07104786Phase 2CompletedPrimary

Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease

NCT06888570Enrolling By Invitation

Relationship Between Eating Patterns, Body Composition and the Detection of Fatty Liver in Children and Adolescents With Trisomy 21: LiverTy Project

NCT01834300Not ApplicableCompletedPrimary

The Effect of Exercise Intervention on Insulin Resistance in Non-alcoholic Fatty Liver Disease (NAFLD)

NCT06623539Phase 2Active Not RecruitingPrimary

Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease

NCT01842282Phase 2Terminated

Amlexanox for Type 2 Diabetes and Obesity

NCT06080386UnknownPrimary

UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)

NCT05426382Not ApplicableCompletedPrimary

A Digital Solution for Individuals With Non Alcoholic Fatty Liver Disease

NCT02941549Phase 2CompletedPrimary

Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD

NCT01634048Not ApplicableCompleted

The Effect of Protein-enriched Diet on Body Composition and Appetite

NCT03135873Not ApplicableCompletedPrimary

Mastiha Treatment for Obese With NAFLD Diagnosis

NCT04442620Not ApplicableUnknownPrimary

Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity

NCT03590626Not ApplicableCompletedPrimary

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

NCT03850886Phase 2CompletedPrimary

Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients

NCT02686476Not ApplicableCompletedPrimary

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

NCT03300661Not ApplicableCompletedPrimary

Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine

NCT01874249Not ApplicableCompletedPrimary

Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease

Scroll to load more

Research Network

Activity Timeline